Skip to main content
Erschienen in: Strahlentherapie und Onkologie 10/2014

01.10.2014 | Original article

MRI-detected skull-base invasion

Prognostic value and therapeutic implication in intensity-modulated radiotherapy treatment for nasopharyngeal carcinoma

verfasst von: Yi-Kan Cheng, M.D., Li-Zhi Liu, M.D., Ning Jiang, M.D., Dan Yue, M.D., Ling-Long Tang, M.D., Fan Zhang, M.D., Li Lin, M.D., Xu Liu, M.D., Lei Chen, Jun Ma, M.D.

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

With advances in imaging and radiotherapy, the prognostic value of skull-base invasion in nasopharyngeal carcinoma (NPC) needs to be reassessed. We aimed to define a classification system and evaluate the prognostic value of the classification of magnetic resonance imaging (MRI)-detected skull-base invasion in NPC treated with intensity-modulated radiotherapy (IMRT).

Patients and materials

We retrospectively reviewed 749 patients who underwent MRI and were subsequently histologically diagnosed with nondisseminated NPC and treated with IMRT.

Results

MRI-detected skull-base invasion was not found to be an independent prognostic factor for overall survival (OS), distant metastasis-free survival (DMFS), local relapse-free survival (LRFS), or disease-free survival (DFS; p > 0.05 for all). Skull-base invasion was classified according to the incidence of each site (type I sites inside pharyngobasilar fascia and clivus vs. type II sites outside pharyngobasilar fascia). The 5-year OS, DMFS, LRFS, and DFS rates in the classification of skull-base invasion in NPC were 83 vs. 67 %, 85 vs.75 %, 95 vs. 88 %, and 76 vs. 62 %, respectively (p < 0.05 for all). Multivariate analysis indicated the classification of skull-base invasion was an independent prognostic factor.

Conclusion

MRI-detected skull-base invasion is not an independent prognostic factor in patients with NPC treated with IMRT. However, classification according to the site of invasion has prognostic value. Therefore, patients with various subclassifications of stage T3 disease may receive treatment with different intensities; however, further studies are warranted to prove this.
Literatur
1.
Zurück zum Zitat Lai SZ, Li WF, Chen L et al (2011) How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys 80:661–668PubMedCrossRef Lai SZ, Li WF, Chen L et al (2011) How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys 80:661–668PubMedCrossRef
2.
Zurück zum Zitat Lee AW, Sze WM, Au JS et al (2005) Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 61:1107–1116PubMedCrossRef Lee AW, Sze WM, Au JS et al (2005) Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 61:1107–1116PubMedCrossRef
3.
Zurück zum Zitat Heng DM, Wee J, Fong KW et al (1999) Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer 86:1912–1920PubMedCrossRef Heng DM, Wee J, Fong KW et al (1999) Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer 86:1912–1920PubMedCrossRef
4.
Zurück zum Zitat Edge SB, Compton CC, Edge SB, Byrd DR, Compton CC (2009) AJCC cancer staging manual, 7th edn. Lippincott-Raven, Philadelphia Edge SB, Compton CC, Edge SB, Byrd DR, Compton CC (2009) AJCC cancer staging manual, 7th edn. Lippincott-Raven, Philadelphia
5.
Zurück zum Zitat Chong VF, Fan YF (1996) Skull base erosion in nasopharyngeal carcinoma: detection by CT and MRI. Clin Radiol 51:625–631PubMedCrossRef Chong VF, Fan YF (1996) Skull base erosion in nasopharyngeal carcinoma: detection by CT and MRI. Clin Radiol 51:625–631PubMedCrossRef
6.
Zurück zum Zitat Ng SH, Chang TC, Ko SF et al (1997) Nasopharyngeal carcinoma: MRI and CT assessment. Neuroradiology 39:741–746PubMedCrossRef Ng SH, Chang TC, Ko SF et al (1997) Nasopharyngeal carcinoma: MRI and CT assessment. Neuroradiology 39:741–746PubMedCrossRef
7.
Zurück zum Zitat Chen L, Liu LZ, Mao YP et al (2011) Grading of MRI-detected skull-base invasion in nasopharyngeal carcinoma and its prognostic value. Head Neck 33:1309–1314PubMedCrossRef Chen L, Liu LZ, Mao YP et al (2011) Grading of MRI-detected skull-base invasion in nasopharyngeal carcinoma and its prognostic value. Head Neck 33:1309–1314PubMedCrossRef
8.
Zurück zum Zitat Lu JC, Wei BQ, Chen WZ et al (2006) Staging of nasopharyngeal carcinoma investigated by magnetic resonance imaging. Radiother Oncol 79:21–26PubMedCrossRef Lu JC, Wei BQ, Chen WZ et al (2006) Staging of nasopharyngeal carcinoma investigated by magnetic resonance imaging. Radiother Oncol 79:21–26PubMedCrossRef
9.
Zurück zum Zitat Lu JC, Wei Q, Zhang YQ, Li F (2004) Influence of MRI abnormality in skull base bone on prognosis of nasopharyngeal carcinoma. Cancer Radiother 8:230–233PubMedCrossRef Lu JC, Wei Q, Zhang YQ, Li F (2004) Influence of MRI abnormality in skull base bone on prognosis of nasopharyngeal carcinoma. Cancer Radiother 8:230–233PubMedCrossRef
10.
Zurück zum Zitat Chen JL, Huang YS, Kuo SH et al (2013) Intensity-modulated radiation therapy for T4 nasopharyngeal carcinoma: treatment results and locoregional recurrence. Strahlenther Onkol 189:1001–1008PubMedCrossRef Chen JL, Huang YS, Kuo SH et al (2013) Intensity-modulated radiation therapy for T4 nasopharyngeal carcinoma: treatment results and locoregional recurrence. Strahlenther Onkol 189:1001–1008PubMedCrossRef
11.
Zurück zum Zitat Hsiung CY, Hunt MA, Yorke ED et al (2005) Intensity-modulated radiotherapy as the boost or salvage treatment of nasopharyngeal carcinoma: the appropriate parameters in the inverse planning and the effect of patient’s anatomic factors on the planning results. Radiother Oncol 77:53–57PubMedCrossRef Hsiung CY, Hunt MA, Yorke ED et al (2005) Intensity-modulated radiotherapy as the boost or salvage treatment of nasopharyngeal carcinoma: the appropriate parameters in the inverse planning and the effect of patient’s anatomic factors on the planning results. Radiother Oncol 77:53–57PubMedCrossRef
12.
Zurück zum Zitat Uzel EK, Karacam S, Elicin O, Uzel O (2013) Comparison of two different IMRT planning techniques in the treatment of nasopharyngeal carcinoma. Effect on parotid gland radiation doses. Strahlenther Onkol 189:552–558PubMedCrossRef Uzel EK, Karacam S, Elicin O, Uzel O (2013) Comparison of two different IMRT planning techniques in the treatment of nasopharyngeal carcinoma. Effect on parotid gland radiation doses. Strahlenther Onkol 189:552–558PubMedCrossRef
13.
Zurück zum Zitat Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ (2004) The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 22:4604–4612PubMedCrossRef Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ (2004) The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 22:4604–4612PubMedCrossRef
14.
Zurück zum Zitat Tang LL, Sun Y, Mao YP et al (2013) Prognostic value of parapharyngeal extension in nasopharyngeal carcinoma treated with intensity modulated radiotherapy. Radiother Oncol pii:S0167-8140(13)00511-2 Tang LL, Sun Y, Mao YP et al (2013) Prognostic value of parapharyngeal extension in nasopharyngeal carcinoma treated with intensity modulated radiotherapy. Radiother Oncol pii:S0167-8140(13)00511-2
15.
Zurück zum Zitat Zhao C, Han F, Lu LX et al (2004) [Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma]. Ai Zheng 23:1532–1537PubMed Zhao C, Han F, Lu LX et al (2004) [Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma]. Ai Zheng 23:1532–1537PubMed
16.
Zurück zum Zitat Liang SB, Sun Y, Liu LZ et al (2009) Extension of local disease in nasopharyngeal carcinoma detected by magnetic resonance imaging: improvement of clinical target volume delineation. Int J Radiat Oncol Biol Phys 75:742–750PubMedCrossRef Liang SB, Sun Y, Liu LZ et al (2009) Extension of local disease in nasopharyngeal carcinoma detected by magnetic resonance imaging: improvement of clinical target volume delineation. Int J Radiat Oncol Biol Phys 75:742–750PubMedCrossRef
17.
Zurück zum Zitat Nishioka T, Shirato H, Kagei K et al (2000) Skull-base invasion of nasopharyngeal carcinoma: magnetic resonance imaging findings and therapeutic implications. Int J Radiat Oncol Biol Phys 47:395–400PubMedCrossRef Nishioka T, Shirato H, Kagei K et al (2000) Skull-base invasion of nasopharyngeal carcinoma: magnetic resonance imaging findings and therapeutic implications. Int J Radiat Oncol Biol Phys 47:395–400PubMedCrossRef
18.
Zurück zum Zitat Liu L, Liang S, Li L et al (2009) Prognostic impact of magnetic resonance imaging-detected cranial nerve involvement in nasopharyngeal carcinoma. Cancer 115:1995–2003PubMedCrossRef Liu L, Liang S, Li L et al (2009) Prognostic impact of magnetic resonance imaging-detected cranial nerve involvement in nasopharyngeal carcinoma. Cancer 115:1995–2003PubMedCrossRef
19.
Zurück zum Zitat Batsakis JG (1985) Nerves and neurotropic carcinomas. Ann Otol Rhinol Laryngol 94:426–427PubMed Batsakis JG (1985) Nerves and neurotropic carcinomas. Ann Otol Rhinol Laryngol 94:426–427PubMed
20.
Zurück zum Zitat Guo R, Sun Y, Yu XL et al (2012) Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma? Radiother Oncol 104:294–299PubMedCrossRef Guo R, Sun Y, Yu XL et al (2012) Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma? Radiother Oncol 104:294–299PubMedCrossRef
21.
Zurück zum Zitat Chan AT, Hsu MM, Goh BC et al (2005) Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 23:3568–3576PubMedCrossRef Chan AT, Hsu MM, Goh BC et al (2005) Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 23:3568–3576PubMedCrossRef
22.
Zurück zum Zitat Ng SH, Chan SC Yen TC et al (2009) Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging 36:12–22PubMedCrossRef Ng SH, Chan SC Yen TC et al (2009) Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging 36:12–22PubMedCrossRef
Metadaten
Titel
MRI-detected skull-base invasion
Prognostic value and therapeutic implication in intensity-modulated radiotherapy treatment for nasopharyngeal carcinoma
verfasst von
Yi-Kan Cheng, M.D.
Li-Zhi Liu, M.D.
Ning Jiang, M.D.
Dan Yue, M.D.
Ling-Long Tang, M.D.
Fan Zhang, M.D.
Li Lin, M.D.
Xu Liu, M.D.
Lei Chen
Jun Ma, M.D.
Publikationsdatum
01.10.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 10/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-014-0656-7

Weitere Artikel der Ausgabe 10/2014

Strahlentherapie und Onkologie 10/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.